Literature DB >> 18403721

Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis.

Wanda J Kozlowska1, Andrew Bush, Angela Wade, Paul Aurora, Siobhán B Carr, Rosie A Castle, Ah-Fong Hoo, Sooky Lum, John Price, Sarath Ranganathan, Clare Saunders, Sanja Stanojevic, John Stroobant, Colin Wallis, Janet Stocks.   

Abstract

RATIONALE: After recent standardization of forced expiratory maneuvers for both infants and preschool children, longitudinal measurements are now possible from birth.
OBJECTIVES: The aim of this study was to investigate the evolution of lung function during the first 6 years of life after a clinical diagnosis of cystic fibrosis (CF) in infancy in children with CF and in healthy control subjects.
METHODS: The raised volume technique was used during infancy and incentive spirometry during the preschool years.
MEASUREMENTS AND MAIN RESULTS: Forty-eight children with CF and 33 healthy control subjects had up to seven (median, 3) measurements. Over these early years, the diagnosis of CF itself accounted for a significant mean reduction of 7.5% (95% confidence interval, 0.9 - 13.6%) in FEV(0.75) and 15.1% (95% confidence interval, 3.6 - 25.3%) in FEF(25-75). Wheeze on auscultation, recent cough, and Pseudomonas aeruginosa (PsA) infection (even if apparently effectively treated) were all independently associated with further reductions in lung function. Premorbid lung function did not predict infection with PsA.
CONCLUSIONS: This is the first study to describe physiologic measurements from infancy through the preschool years in subjects with CF and healthy control subjects, the understanding of which is critical for future intervention trials. Airflow obstruction in uncomplicated CF persists through the preschool years despite treatment, with PsA acquisition being associated with further deterioration in lung function, even when apparently eradicated. This suggests that new therapies are needed to treat the airflow obstruction of uncomplicated CF, and rigorous strategies to prevent PsA acquisition.

Entities:  

Mesh:

Year:  2008        PMID: 18403721     DOI: 10.1164/rccm.200710-1599OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

Review 1.  Vitamin E supplementation in people with cystic fibrosis.

Authors:  Peter O Okebukola; Sonal Kansra; Joanne Barrett
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Margaret Rosenfeld; Ronald L Gibson; George Z Retsch-Bogart; Julia Emerson; Valeria Thompson; Bonnie W Ramsey
Journal:  Clin Infect Dis       Date:  2015-05-13       Impact factor: 9.079

4.  Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis.

Authors:  E Hatziagorou; V Avramidou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

5.  Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.

Authors:  Margaret Rosenfeld; Stephanie Davis; Lyndia Brumback; Stephen Daniel; Ron Rowbotham; Robin Johnson; Sharon McNamara; Renee Jensen; Carol Barlow; Felix Ratjen
Journal:  Pediatr Pulmonol       Date:  2011-03-01

6.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

Review 7.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

8.  Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease.

Authors:  Jessica E Pittman; Elizabeth H Calloway; Michelle Kiser; John Yeatts; Stephanie D Davis; Mitchell L Drumm; Michael S Schechter; Margaret W Leigh; Mary Emond; Annelies Van Rie; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2010-12-30

9.  Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis.

Authors:  Margaret Rosenfeld; Philip M Farrell; Margaret Kloster; Jonathan O Swanson; Thuy Vu; Lyndia Brumback; James D Acton; Robert G Castile; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Gwendolyn S Kerby; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie D Davis
Journal:  Eur Respir J       Date:  2013-05-30       Impact factor: 16.671

10.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.